Drug Trial Radar · NCT00127179
A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)
Last checked: Nov 19, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
600
Actual
Start
Jan 1, 2004
Primary completion
Jul 1, 2005
Study completion Jul 25, 2005
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Aug 5, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 50 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.
Conditions
- Benign Prostatic Hyperplasia
Interventions
MK0906, finasteride / Duration of Treatment: 48 weeksDrug
Comparator: placebo / Duration of Treatment: 48 weeksDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the International Prostate Symptom Score
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.